Merck's WINREVAIR Phase 2 CADENCE Trial Shows Positive Proof-of-Concept In Pulmonary Hypertension

Merck announced detailed results from the Phase 2 CADENCE study evaluating two doses (0.3 mg/kg and 0.7 mg/kg) of WINREVAIR (sotatercept-csrk) for adults with the syndrome of combined post- and pr... The article notes the trial assessed efficacy, safety and tolerability but the excerpt is truncated and provides no outcome metrics, so immediate market implications are limited.

Analysis

Merck announced detailed results from the Phase 2 CADENCE study evaluating two doses (0.3 mg/kg and 0.7 mg/kg) of WINREVAIR (sotatercept-csrk) for adults with the syndrome of combined post- and pr... The article notes the trial assessed efficacy, safety and tolerability but the excerpt is truncated and provides no outcome metrics, so immediate market implications are limited.